Armistice Capital, LLC Clovis Oncology, Inc. Call Options Transaction History

Armistice Capital, LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $60,000 - $328,600	-20,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $8.63 Million - $33.7 Million	-2,195,600 Reduced 99.1%	20,000 $7.86 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $28.4 Million - $56.9 Million	2,215,600 New	2,215,600 $32.9 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.